

22. Windrum P, Hull DR, Morris TC. Herb–drug interactions. *Lancet* 2000;355:1019-20.
23. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. *Evidence-based medicine: how to practice and teach EBM*. 2nd ed. London: Churchill Livingstone; 2000.
24. Olatunbosun OA, Edouard L, Pierson RA. Physicians' attitudes toward evidence-based obstetric practice: a questionnaire survey. *BMJ* 1998;316:365-6.
25. McAlister FA, Graham I, Karr GW, Laupacis A. Evidence-based medicine and the practicing clinician. *J Gen Intern Med* 1999;14(4):236-42.
26. Charlton BG. Restoring the balance: evidence-based medicine put in its place. *J Eval Clin Pract* 1997;3:87-98.
27. Porzsolt F, Sellenthin C. Der sechste Schritt in der Anwendung der Evidence-Based Medicine. *Z Aerztl Fortbild Qual Sich* 2000;94:619-20. Available: www.uni-ulm.de/cebm/Publikationen/Sechster_Schritt/sechster_schritt.html
28. Bauer R. Quality criteria and standardization of phytopharmaceuticals: Can acceptable drug standards be achieved? *Drug Inf J* 1998;32:101-10.
29. Busse W. The significance of quality for efficacy and safety of herbal medicinal products. *Drug Inf J* 2000;34:15-23.
30. Guyatt G, Rennie D, editors. *Users' guides to the medical literature: A manual for evidence-based clinical practice*. Chicago: American Medical Association; 2002.
31. Chandler F, editor. *Herbs: everyday reference for health professionals*. Ottawa: Canadian Pharmacists Association and Canadian Medical Association; 2000.
32. Huang WF, Wen KC, Hsiao ML. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. *J Clin Pharmacol* 1997;37:344-50.
33. Gaus W, Hogel J. Studies on the efficacy of unconventional therapies. Problems and designs. *Arzneimittelforschung* 1995;45:88-92.
34. Henney JE. From the Food and Drug Administration: Risk of drug interactions with St John's wort. *JAMA* 2000;283(13):1679.
35. Wharry S. Health Canada sounds warning over St John's wort. *CMAJ* 2000;162:1723.
36. Phillips R, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, et al. Levels of evidence and grades of recommendations. Oxford: Centre for Evidence-Based Medicine; 2001. <http://www.minervation.com/cebm/docs/levels.html> (accessed 23 Jul 2002).
37. Linde K, Mulrow CD. St John's wort for depression [Cochrane review]. In: *The Cochrane Library*; Issue 2, 2002. Oxford: Update Software.
38. Guyatt GH, Meade MO, Jaeschke RZ, Cook DJ, Haynes RB. Practitioners of evidence based care. Not all clinicians need to appraise evidence from scratch but all need some skills. *BMJ* 2000;320:954-5.
39. Pittler M, Edzard E. Kava extract for treating anxiety [Cochrane review]. In: *The Cochrane Library*; Issue 4, 2001. Oxford: Update Software.
40. Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomised clinical trials: Is blinding necessary? *Control Clin Trials* 1996;17:1-12.

Notice of competing interests

The competing interests statements that were not available when the July 2002 issue of the *Journal of Psychiatry & Neuroscience* went to press appear below.

For: Tranter R, O'Donovan C, Chandarana P, Kennedy S. Prevalence and outcome of partial remission in depression. *J Psychiatry Neurosci* 2002;27(4):241-7.

Dr. O'Donovan has received consultancy fees from Eli Lilly, an honorarium for participating in the development of the article from Wyeth-Ayerst and speaker fees from Eli Lilly and GlaxoSmithKline.

For: Segal Z, Vincent P, Levitt A. Efficacy of combined, sequential and crossover psychotherapy and pharmacotherapy in improving outcomes in depression. *J Psychiatry Neurosci* 2002;27(4):281-90.

Dr. Vincent has served on advisory boards for Organon and Eli Lilly and has received speaker fees from Pharmacia, Organon and Eli Lilly.

Dr. Levitt has received consultancy fees from Eli Lilly and Janssen-Ortho; speaker fees from Wyeth-Ayerst, Lundbeck, Eli Lilly and Janssen-Ortho; and travel assistance from Wyeth-Ayerst.